AAV9-mediated targeting of natural antisense transcript as a novel treatment for Dravet syndrome

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Dravet syndrome (DS) is a severe childhood epileptic encephalopathy characterized by prolonged seizures, developmental delay, intellectual disability, and high mortality.
• Mutations in the SCN1A gene, encoding the Na_V1.1 sodium channel, are found in approximately 90% of DS patients.
• A specific long non-coding RNA (lncRNA) downregulates SCN1A expression, and its activity can be modulated by AntagoNATs.

Purpose of the Study:

• To develop and evaluate novel AntagoNATs delivered via adeno-associated virus serotype 9 (AAV9) gene therapy vectors for Dravet syndrome.
• To assess the efficacy of AAV9-AntagoNAT vectors in improving survival and reducing seizure frequency in a mouse model of DS.

Main Methods:

• Development of new AntagoNATs and their incorporation into AAV9 gene therapy vectors (AAV9-AntagoNAT-H and AntagoNAT-K).
• Administration of AAV9-AntagoNAT vectors to newborn Scn1a^+/- mice via intracerebroventricular (i.c.v.) and intravenous (i.v.) injections.
• Evaluation of therapeutic effects on survival rates and seizure frequency (febrile and spontaneous).

Main Results:

• AAV9-AntagoNAT-H administration significantly increased survival rates in treated mice.
• A significant decrease in the frequency of both febrile and spontaneous seizures was observed.
• This study demonstrates the successful delivery of AntagoNATs using an AAV9 vector in a DS mouse model.

Conclusions:

• Delivery of AntagoNATs via AAV9 vectors represents a promising gene therapy strategy for Dravet syndrome.
• This approach has the potential to offer a one-time treatment option for DS patients by targeting SCN1A regulation.
• Further research is warranted to translate these findings into clinical applications for Dravet syndrome.